CN1643149A - 高效表达两种不同类型肝细胞生长因子的杂合肝细胞生长因子基因 - Google Patents
高效表达两种不同类型肝细胞生长因子的杂合肝细胞生长因子基因 Download PDFInfo
- Publication number
- CN1643149A CN1643149A CNA038065347A CN03806534A CN1643149A CN 1643149 A CN1643149 A CN 1643149A CN A038065347 A CNA038065347 A CN A038065347A CN 03806534 A CN03806534 A CN 03806534A CN 1643149 A CN1643149 A CN 1643149A
- Authority
- CN
- China
- Prior art keywords
- hgf
- gene
- pck
- pcp
- dhgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title abstract description 18
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 title abstract 7
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 208000023589 ischemic disease Diseases 0.000 claims abstract description 3
- 208000019423 liver disease Diseases 0.000 claims abstract description 3
- 101150022655 HGF gene Proteins 0.000 claims description 58
- 244000005700 microbiome Species 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 abstract description 42
- 108700024394 Exon Proteins 0.000 abstract description 4
- 230000000302 ischemic effect Effects 0.000 abstract description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 42
- 239000012634 fragment Substances 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 20
- 239000000203 mixture Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000013467 fragmentation Methods 0.000 description 8
- 238000006062 fragmentation reaction Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 238000004321 preservation Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- -1 stablizer Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 2
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 2
- 229960001139 cefazolin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000012882 sequential analysis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008359 glycogelatin Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003574 melanophore Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 210000003137 popliteal artery Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003351 stiffener Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
Description
5’端引物 | 3’端引物 | 扩增的片段 |
gHGF3(SEQ ID NO:3) | gHGF4(SEQ ID NO:4) | HGF基因片段2(HGF-F2) |
gHGF3(SEQ ID NO:3) | gHGF10(SEQ ID NO:5) | HGF基因片段3(HGF-F3) |
gHGF5(SEQ ID NO:6) | gHGF7(SEQ ID NO:7) | HGF基因片段5(HGF-F5) |
gHGF12(SEQ ID NO:8) | gHGF7(SEQ ID NO:7) | HGF基因片段7(HGF-F7) |
gHGF13(SEQ ID NO:9) | gHGF7(SEQ ID NO:7) | HGF基因片段8(HGF-F8) |
gHGF6(SEQ ID NO:10) | GHGF7(SEQ ID NO:7) | HGF基因片段6(HGF-F6) |
5’端引物 | 3’端引物 | 扩增产物 |
gHGF1(SEQ ID NO:11) | gHGF2(SEQ ID NO:12) | HGF基因片段1(HGF-F1) |
gHGF8(SEQ ID NO:13) | gHGF9(SEQ ID NO:14) | HGF基因片段4(HGF-F4) |
cHGF5(SEQ ID NO:15) | cHGF3(SEQ ID NO:16) | HGF基因cDNA(cHGF)dHGF基因cDNA(dHGF) |
保藏人 | 百疗医株式会社 |
地址 | 韩国,汉城 |
保藏日 | 2002年3月19日 |
保藏号 | KCCM-10361 |
微生物分类名 | 大肠杆菌ToplOF’pCK-HGFX7 |
国际包藏单位名称 | 韩国微生物培养中心 |
代理机构盖章 |
保藏人 | 百疗医株式会社 |
地址 | 韩国,汉城 |
保藏日 | 2002年3月12日 |
保藏号 | KCCM-10362 |
微生物分类名 | 大肠杆菌ToplOF’pCK-HGFX7 |
国际包藏单位名称 | 韩国微生物培养中心 |
代理机构盖章 |
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0015074 | 2002-03-20 | ||
KR1020020015074A KR100562824B1 (ko) | 2002-03-20 | 2002-03-20 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
KR1020020015074 | 2002-03-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1643149A true CN1643149A (zh) | 2005-07-20 |
CN100378219C CN100378219C (zh) | 2008-04-02 |
Family
ID=28036130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB038065347A Expired - Lifetime CN100378219C (zh) | 2002-03-20 | 2003-03-20 | 高效表达两种不同类型肝细胞生长因子的杂合肝细胞生长因子基因 |
Country Status (14)
Country | Link |
---|---|
US (5) | US7812146B2 (zh) |
EP (1) | EP1490492B1 (zh) |
JP (1) | JP4057537B2 (zh) |
KR (1) | KR100562824B1 (zh) |
CN (1) | CN100378219C (zh) |
AT (1) | ATE380826T1 (zh) |
AU (1) | AU2003210053A1 (zh) |
BR (1) | BRPI0303570B8 (zh) |
DE (1) | DE60318026T2 (zh) |
DK (1) | DK1490492T3 (zh) |
ES (1) | ES2298538T3 (zh) |
HK (1) | HK1080895A1 (zh) |
PT (1) | PT1490492E (zh) |
WO (1) | WO2003078568A2 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011082694A1 (zh) * | 2010-01-11 | 2011-07-14 | 上海优益基国际贸易有限公司 | 血运重建基因药物靶向投递缓释支架 |
CN107073078A (zh) * | 2014-09-26 | 2017-08-18 | 百疗医株式会社 | 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物 |
CN108611367A (zh) * | 2018-04-24 | 2018-10-02 | 北京诺思兰德生物技术股份有限公司 | 一类通过质粒载体介导的基因治疗重组载体 |
CN110747214A (zh) * | 2019-03-13 | 2020-02-04 | 深圳市臻质医疗科技有限公司 | DNA片段、具有长效表达和细胞特异性结合能力的mRNA-抗体融合分子及其制备方法 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
CA2628928A1 (en) * | 2005-11-10 | 2007-05-24 | Receptor Biologix, Inc. | Hepatocyte growth factor intron fusion proteins |
US20090202606A1 (en) * | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
AU2009234598C1 (en) * | 2008-04-09 | 2012-08-23 | Viromed Co., Ltd. | Lyophilized DNA formulations for enhanced expression of plasmid DNA |
EP2216399A1 (en) * | 2009-01-30 | 2010-08-11 | Université de la Méditerranée | Human soluble CD146, preparation and uses thereof |
JP6240337B2 (ja) | 2013-10-22 | 2017-11-29 | バイロメッド カンパニー リミテッド | 肝細胞増殖因子の2つ以上のアイソフォームを利用した筋萎縮性側索硬化症の予防又は治療用組成物 |
WO2017135795A1 (ko) * | 2016-02-04 | 2017-08-10 | 주식회사 에스엘바이젠 | 간세포성장인자를 발현하는 중간엽줄기세포 및 이의 용도 |
EP3733855A4 (en) * | 2017-12-29 | 2021-03-03 | Helixmith Co., Ltd | ADENO-ASSOCIATED VIRUS (AAV) VECTOR INCLUDING A HYBRID HGF GENE INTRODUCED INTO ITS BREAST |
KR102245539B1 (ko) | 2018-02-12 | 2021-04-29 | 주식회사 지앤피바이오사이언스 | 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물 |
US20190381138A1 (en) * | 2018-05-17 | 2019-12-19 | Helixmith Co., Ltd. | Treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy |
EP3823981A4 (en) * | 2018-07-17 | 2022-04-06 | Neuromyon Inc. | TREATMENT OF NEUROPATHY WITH DNA CONSTRUCTS EXPRESSING IGF-1 ISOFORMS |
EP3823677A4 (en) | 2018-07-19 | 2022-06-01 | Helixmith Co., Ltd. | FREEZE-DRIED PHARMACEUTICAL COMPOSITIONS INTENDED FOR NAKED-DNA GENE THERAPY |
KR20210035126A (ko) | 2021-03-18 | 2021-03-31 | 주식회사 지앤피바이오사이언스 | 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물 |
WO2022211454A1 (ko) * | 2021-03-29 | 2022-10-06 | 주식회사 헬릭스미스 | 샤르코-마리-투스병 예방 또는 치료용 약제학적 조성물 |
US20230212603A1 (en) * | 2021-10-06 | 2023-07-06 | G&P Bioscience Co., Ltd. | Development of optimized recombinant expression construct |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ232813A (en) * | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6673776B1 (en) * | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
CA2022752C (en) * | 1989-08-11 | 1998-07-07 | Naomi Kitamura | Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor |
US6706694B1 (en) * | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
DK0539590T3 (da) * | 1990-07-13 | 1999-10-11 | Snow Brand Milk Products Co Ltd | Plasmid indeholdende DNA, som koder for aminosyresekvensen af TCF-II, en transformeret celle og fremstilling af et fysiolog |
US5661133B1 (en) * | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
US6498144B1 (en) * | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
US5837676A (en) * | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
US5652225A (en) * | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
DE69634567T2 (de) * | 1995-08-29 | 2006-02-16 | Anges Mg Inc., Toyonaka | Ein medikament,das hgf gen enthält |
US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
US6121246A (en) * | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
JP2002515065A (ja) | 1997-05-06 | 2002-05-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脈管形成トランスジーンのインビボ送達により心不全および心室再構成を処置するための技術および組成物 |
JPH11246433A (ja) | 1998-03-03 | 1999-09-14 | Sumitomo Pharmaceut Co Ltd | 心筋梗塞治療剤 |
AU766238B2 (en) | 1998-03-09 | 2003-10-09 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Compositions and methods for modulating vascularization |
US20040228834A1 (en) * | 1998-03-09 | 2004-11-18 | Jeffrey Isner | Compositions and methods for modulating vascularization |
AU5065599A (en) * | 1998-08-05 | 2000-02-28 | Sumitomo Pharmaceuticals Company, Limited | Preparations for the administration of hepatocyte growth factor |
CN1182874C (zh) * | 1999-10-29 | 2005-01-05 | 安增子摩祺株式会社 | 糖尿病性局部缺血疾病的基因治疗制剂 |
EP1225921A1 (en) | 1999-11-05 | 2002-07-31 | The Regents of the University of California | TECHNIQUES AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE BY i IN VIVO /i GENE DELIVERY |
CN1142272C (zh) * | 2000-02-02 | 2004-03-17 | 中国人民解放军军事医学科学院百环生物医学研究中心 | 携带人肝细胞生长因子基因的重组腺病毒的用途 |
DE60134021D1 (de) * | 2000-06-27 | 2008-06-26 | Anges Mg Inc | Pharmazeutische zubereitungen zur angiogenese-therapie |
US20020172663A1 (en) * | 2001-01-23 | 2002-11-21 | Maria Palasis | Localized myocardial injection method for treating ischemic myocardium |
KR100562824B1 (ko) * | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
WO2006121532A2 (en) * | 2005-03-31 | 2006-11-16 | Mytogen, Inc. | Treatment for heart disease |
US20090202606A1 (en) * | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
AU2009234598C1 (en) * | 2008-04-09 | 2012-08-23 | Viromed Co., Ltd. | Lyophilized DNA formulations for enhanced expression of plasmid DNA |
-
2002
- 2002-03-20 KR KR1020020015074A patent/KR100562824B1/ko active IP Right Grant
-
2003
- 2003-03-20 EP EP03744561A patent/EP1490492B1/en not_active Expired - Lifetime
- 2003-03-20 AU AU2003210053A patent/AU2003210053A1/en not_active Abandoned
- 2003-03-20 DE DE60318026T patent/DE60318026T2/de not_active Expired - Lifetime
- 2003-03-20 AT AT03744561T patent/ATE380826T1/de active
- 2003-03-20 BR BRPI0303570A patent/BRPI0303570B8/pt not_active IP Right Cessation
- 2003-03-20 ES ES03744561T patent/ES2298538T3/es not_active Expired - Lifetime
- 2003-03-20 CN CNB038065347A patent/CN100378219C/zh not_active Expired - Lifetime
- 2003-03-20 WO PCT/KR2003/000548 patent/WO2003078568A2/en active IP Right Grant
- 2003-03-20 DK DK03744561T patent/DK1490492T3/da active
- 2003-03-20 JP JP2003576563A patent/JP4057537B2/ja not_active Expired - Lifetime
- 2003-03-20 PT PT03744561T patent/PT1490492E/pt unknown
-
2004
- 2004-09-20 US US10/944,277 patent/US7812146B2/en active Active
-
2006
- 2006-01-17 HK HK06100717A patent/HK1080895A1/xx not_active IP Right Cessation
-
2007
- 2007-12-14 US US11/957,170 patent/US7838505B2/en not_active Expired - Lifetime
-
2009
- 2009-12-31 US US12/650,860 patent/US7745174B2/en not_active Ceased
-
2010
- 2010-10-20 US US12/908,765 patent/US8338385B2/en not_active Expired - Lifetime
-
2017
- 2017-07-05 US US15/642,307 patent/USRE48404E1/en not_active Expired - Lifetime
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011082694A1 (zh) * | 2010-01-11 | 2011-07-14 | 上海优益基国际贸易有限公司 | 血运重建基因药物靶向投递缓释支架 |
CN107073078A (zh) * | 2014-09-26 | 2017-08-18 | 百疗医株式会社 | 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物 |
US11219667B2 (en) | 2014-09-26 | 2022-01-11 | Helixmith Co., Ltd. | Method for treating peripheral vascular disease using hepatocyte growth factor and stromal cell derived factor 1A |
CN108611367A (zh) * | 2018-04-24 | 2018-10-02 | 北京诺思兰德生物技术股份有限公司 | 一类通过质粒载体介导的基因治疗重组载体 |
CN110747214A (zh) * | 2019-03-13 | 2020-02-04 | 深圳市臻质医疗科技有限公司 | DNA片段、具有长效表达和细胞特异性结合能力的mRNA-抗体融合分子及其制备方法 |
CN110747214B (zh) * | 2019-03-13 | 2021-12-31 | 深圳市臻质医疗科技有限公司 | DNA片段、具有长效表达和细胞特异性结合能力的mRNA-抗体融合分子及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US7745174B2 (en) | 2010-06-29 |
JP2005520512A (ja) | 2005-07-14 |
US20120010273A1 (en) | 2012-01-12 |
USRE48404E1 (en) | 2021-01-26 |
US20050079581A1 (en) | 2005-04-14 |
DE60318026T2 (de) | 2008-11-20 |
CN100378219C (zh) | 2008-04-02 |
AU2003210053A8 (en) | 2003-09-29 |
US20100105878A1 (en) | 2010-04-29 |
US7812146B2 (en) | 2010-10-12 |
HK1080895A1 (en) | 2006-05-04 |
KR20030075718A (ko) | 2003-09-26 |
JP4057537B2 (ja) | 2008-03-05 |
DK1490492T3 (da) | 2008-03-17 |
WO2003078568A2 (en) | 2003-09-25 |
AU2003210053A1 (en) | 2003-09-29 |
DE60318026D1 (de) | 2008-01-24 |
US7838505B2 (en) | 2010-11-23 |
US8338385B2 (en) | 2012-12-25 |
EP1490492A4 (en) | 2006-05-31 |
KR100562824B1 (ko) | 2006-03-23 |
EP1490492A2 (en) | 2004-12-29 |
US20090131350A1 (en) | 2009-05-21 |
EP1490492B1 (en) | 2007-12-12 |
WO2003078568A3 (en) | 2003-11-27 |
BRPI0303570B8 (pt) | 2021-05-25 |
PT1490492E (pt) | 2008-03-25 |
ES2298538T3 (es) | 2008-05-16 |
BRPI0303570B1 (pt) | 2018-04-24 |
ATE380826T1 (de) | 2007-12-15 |
BR0303570A (pt) | 2005-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1643149A (zh) | 高效表达两种不同类型肝细胞生长因子的杂合肝细胞生长因子基因 | |
CN1231595C (zh) | 通过分子伴侣的共分泌制备天然折叠的和分泌的蛋白质的方法 | |
CN1132845C (zh) | 获得具有正确键合的胱氨酸键的胰岛素前体的改进的方法 | |
CN1671423A (zh) | 新型嵌合cd154 | |
CN1195859C (zh) | 修饰化人源粒细胞-集落刺激因子及其制备方法 | |
CN1958794A (zh) | 人肿瘤坏死因子相关凋亡诱导配体突变体编码cDNA及制备方法和应用 | |
CN1154727C (zh) | 人甲状旁腺素的重组表达载体 | |
CN1256347C (zh) | 激肽原第五结构域-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途 | |
CN1778930A (zh) | 激发机体抗鸡球虫感染的融合基因及其编码蛋白与应用 | |
CN1170931C (zh) | 血管发生相关分子 | |
CN1283793C (zh) | 具有骨骼肌刺激活性和免疫调节作用的趋化素样因子超家族 | |
CN1286973C (zh) | 一种组蛋白甲基转移酶及其制备方法 | |
CN1629194A (zh) | 一种可用以抗癌治疗的超抗原融合蛋白质及其生产方法 | |
CN1948339A (zh) | 端粒酶活性抑制蛋白的制备和纯化 | |
CN1827640A (zh) | 血管生成抑制多肽及其制备方法和应用 | |
CN1170850C (zh) | 人血管生成素样蛋白和编码序列及其用途 | |
CN1891718A (zh) | 融合免疫毒素ml-l-sec2和基因及其制备 | |
CN1954882A (zh) | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 | |
CN1304425C (zh) | 含可溶性肿瘤坏死因子II型受体和白介素I受体拮抗剂IL1Ra的融合蛋白及其制备方法 | |
CN1303102C (zh) | 利用人和鼠Rhor基因及其编码产物诊断和治疗秃发的方法 | |
CN100338091C (zh) | 编码新的融合蛋白的dna和通过该dna的表达来制备有用的多肽的方法 | |
CN1186448C (zh) | 重组人α胸腺素原-白介素2基因及其表达、应用 | |
CN1241941C (zh) | 一种促进神经分化和抗细胞凋亡的蛋白质及其编码基因 | |
CN1547610A (zh) | 用于生长激素高表达的dna及其应用 | |
CN1495195A (zh) | 表达雄激素受体复合物相关蛋白的转基因动物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: VIROMED CO., LTD.; APPLICANT Free format text: FORMER OWNER: VIROMED CO., LTD. Effective date: 20051104 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20051104 Address after: Seoul, South Kerean Applicant after: VIROMED Co.,Ltd. Co-applicant after: BEIJING NORTHLAND BIOTECH Co.,Ltd. Address before: Seoul, South Kerean Applicant before: VIROMED Co.,Ltd. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1080895 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1080895 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Seoul, South Kerean Co-patentee after: BEIJING NORTHLAND BIOTECH. Co.,Ltd. Patentee after: VIROMED Co.,Ltd. Address before: Seoul, South Kerean Co-patentee before: BEIJING NORTHLAND BIOTECH Co.,Ltd. Patentee before: VIROMED Co.,Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20050720 Assignee: Beijing North Rand Medical Technology Co.,Ltd. Assignor: VIROMED Co.,Ltd.|BEIJING NORTHLAND BIOTECH. Co.,Ltd. Contract record no.: 2012990000839 Denomination of invention: Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor Granted publication date: 20080402 License type: Exclusive License Record date: 20121120 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Beijing North Rand Medical Technology Co.,Ltd. Assignor: VIROMED Co.,Ltd.|BEIJING NORTHLAND BIOTECH. Co.,Ltd. Contract record no.: 2012990000839 Date of cancellation: 20190513 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
CP01 | Change in the name or title of a patent holder |
Address after: Seoul, South Kerean Patentee after: Helismith Corp. Address before: Seoul, South Kerean Patentee before: VIROMED Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190603 Address after: Seoul, South Kerean Patentee after: VIROMED Co.,Ltd. Address before: Seoul, South Kerean Co-patentee before: BEIJING NORTHLAND BIOTECH. Co.,Ltd. Patentee before: VIROMED Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20080402 |